Emergent BioSolutions to supply $1 billion of Anthrax vaccine to US Strategic National Stockpile

Maryland based biopharmaceutical company Emergent BioSolutions Inc has signed a contract to supply the US Government with almost $1 billion worth of anthrax vaccines.

Emergent BioSolutions announced that the US Department of Health and Human Services (HHS) is progressing its anthrax preparedness strategy with multiple contracts for the company’s anthrax vaccines.

Emergent has signed a follow-on contract with the Centers for Disease Control and Prevention (CDC) valued at up to $911 million to supply approximately 29.4 million doses of BioThrax (Anthrax Vaccine Adsorbed) to the Strategic National Stockpile (SNS) by September 2021. BioThrax is the only anthrax vaccine licensed by the US Food and Drug Administration (FDA) and is indicated for both pre-exposure prophylaxis and post-exposure prophylaxis of anthrax disease.

Also the Biomedical Advanced Research and Development Authority (BARDA), a division within the Office of the Assistant Secretary of Preparedness and Response at HHS, issued a notice of intent to procure approximately $100 million of BioThrax for delivery into the SNS within 24 months from the date of contract award, which the company anticipates will be in the first half of 2017. This contract will be separate from and in addition to the follow-on procurement contract with CDC.

On 30 September 30 awarded Emergent a contract valued at up to $1.6 billion for the development and procurement of NuThrax (anthrax vaccine adsorbed with CPG 7909 adjuvant), the company’s next generation anthrax vaccine candidate.

The initial procurement of NuThrax for inclusion in the SNS could be initiated in 2019 following Emergency Use Authorization (EUA) pre-approval by FDA, which based on the current plan, is anticipated at the end of 2018. The contract also includes procurement options for the delivery of an additional 7.5 million to 50 million doses of NuThrax to the SNS. The company anticipates amending this contract simultaneously with the execution of the BARDA BioThrax procurement contract, which will result in a revised total contract value of up to $1.5 billion.

Taken together, the company believes that the CDC and BARDA contract actions reflect the government’s intention to transition the stockpile of anthrax vaccines from BioThrax to NuThrax beginning in 2019.

President and chief executive officer of Emergent BioSolutions Daniel J Abdun-Nabi announced :

“Emergent believes these actions reflect the U.S. government’s continued assessment of anthrax as a high-priority threat and its firm commitment to protect the nation against bioterrorism,” said  “We are pleased to be able to make meaningful contributions to helping the government execute its strategy to achieve its preparedness goals.”

SOURCE : Emergent BioSolutions – Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile [08 Dec ’16]